

# Wim G Goettsch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6234699/publications.pdf>

Version: 2024-02-01

41  
papers

1,004  
citations

687363

13  
h-index

477307

29  
g-index

43  
all docs

43  
docs citations

43  
times ranked

1173  
citing authors

#	ARTICLE	IF	CITATIONS
1	What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews. <i>Value in Health</i> , 2017, 20, 858-865.	0.3	216
2	Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies. <i>Value in Health</i> , 2017, 20, 520-532.	0.3	137
3	The HTA Core Model – 10 Years of Developing an International Framework to Share Multidimensional Value Assessment. <i>Value in Health</i> , 2017, 20, 244-250.	0.3	67
4	Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions. <i>Value in Health</i> , 2019, 22, 1275-1282.	0.3	65
5	Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions. <i>Value in Health</i> , 2012, 15, 954-960.	0.3	51
6	Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 350-357.	4.7	41
7	Improving the Contribution of Regulatory Assessment Reports to Health Technology Assessments – A Collaboration between the European Medicines Agency and the European network for Health Technology Assessment. <i>Value in Health</i> , 2014, 17, 634-641.	0.3	39
8	Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations. <i>Value in Health</i> , 2020, 23, 10-16.	0.3	37
9	Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 684-691.	4.7	34
10	Early Cost-Effectiveness of Onasemnogene Apeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios. <i>Value in Health</i> , 2021, 24, 759-769.	0.3	24
11	The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries. <i>Quality of Life Research</i> , 2017, 26, 2479-2488.	3.1	22
12	The Application and Implications of Novel Deterministic Sensitivity Analysis Methods. <i>Pharmacoeconomics</i> , 2021, 39, 1-17.	3.3	21
13	Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8309.	2.6	20
14	Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 883-893.	2.1	15
15	Use of Social Media in the Assessment of Relative Effectiveness: Explorative Review With Examples From Oncology. <i>JMIR Cancer</i> , 2018, 4, e11.	2.4	15
16	Real World Data in Health Technology Assessment of Complex Health Technologies. <i>Frontiers in Pharmacology</i> , 2022, 13, 837302.	3.5	15
17	The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 321-330.	1.4	14
18	Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 222.	2.4	13

#	ARTICLE	IF	CITATIONS
19	Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 594549.	3.5	12
20	A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care. <i>Frontiers in Endocrinology</i> , 2021, 12, 636959.	3.5	12
21	STANDARDIZED REPORTING FOR RAPID RELATIVE EFFECTIVENESS ASSESSMENTS OF PHARMACEUTICALS. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 488-496.	0.5	11
22	Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations. <i>Drug Discovery Today</i> , 2020, 25, 1223-1231.	6.4	11
23	"Without data, you're just another person with an opinion". Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 147-154.	1.4	11
24	Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e83.	0.5	10
25	Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. <i>Clinical and Translational Science</i> , 2021, 14, 1566-1577.	3.1	10
26	Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib Assessments. <i>Value in Health</i> , 2015, 18, 663-672.	0.3	9
27	Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision-making of oncology medicines. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00742.	2.4	9
28	Reported Challenges in Health Technology Assessment of Complex Health Technologies. <i>Value in Health</i> , 2022, 25, 992-1001.	0.3	9
29	Efficacy gap between phase II and subsequent phase III studies in oncology. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1306-1313.	2.4	8
30	The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. <i>International Journal of Health Policy and Management</i> , 2020, , .	0.9	8
31	Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England. <i>Value in Health</i> , 2022, 25, 390-399.	0.3	8
32	Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials. <i>BMC Medicine</i> , 2021, 19, 307.	5.5	7
33	Information Patients With Melanoma Spontaneously Report About Health-Related Quality of Life on Web-Based Forums: Case Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e27497.	4.3	6
34	Building HTA insights into the drug development plan: Current approaches to seeking early scientific advice from HTA agencies. <i>Drug Discovery Today</i> , 2022, 27, 347-353.	6.4	6
35	PILOTING INTERNATIONAL PRODUCTION OF RAPID RELATIVE EFFECTIVENESS ASSESSMENTS OF PHARMACEUTICALS. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 521-529.	0.5	3
36	Addressing uncertainty in relative effectiveness assessments by HTA organizations. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, e17.	0.5	3

#	ARTICLE	IF	CITATIONS
37	Understanding innovation of health technology assessment methods: the IHTAM framework. International Journal of Technology Assessment in Health Care, 2022, 38, e16.	0.5	2
38	Access to medicines in Turkey: Evaluation of the process of medicines brought from abroad. International Journal of Technology Assessment in Health Care, 2020, 36, 585-591.	0.5	1
39	Bridging health technology assessment and healthcare quality improvement using international consortium of health outcomes measurement standard sets. International Journal of Technology Assessment in Health Care, 2022, 38, .	0.5	1
40	Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile. Frontiers in Pharmacology, 0, 13, .	3.5	1
41	Comment on "Deterministic Sensitivity Analysis Under Ignorance". Pharmacoeconomics, 2021, 39, 1199-1199.	3.3	0